Early Ramucirumab/Paclitaxel vs Continuation of First-line Chemotherapy in Advanced HER2-negative Gastric/Gastroesophageal Cancer
1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group with HR ...
Tag: esophageal cancer
Capecitabine or XELOX did not appear to improve overall survival when compared to PF in patients with advanced Esophageal Squamous Cell Carcinoma
1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy was comparable suggesting single-agent capecitabine ...
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
Zolbetuximab improves survival in patients with advanced or metastatic gastric adenocarcinoma
1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. ...
Simultaneous integrated boost radiation therapy may improve survival rates for esophageal squamous cell carcinoma
1. For patients aged 70 years and older with esophageal squamous cell carcinoma (ESCC), the combination of simultaneous integrated boost ...
Tislelizumab for advanced esophageal squamous cell carcinoma
1. Median overall survival was 17.2 months in the tislelizumab group versus 10.6 months in the placebo group (HR 0.66). ...
Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer
1. In this phase II randomized clinical trial, treatment of patients with locally advanced esophageal squamous cell carcinoma (ESCC) with ...
#StudyGraphics: Gastric bypass surgery may reduce the risk of esophagogastric cancer in patients with obesity
Click to read this study in JAMA Surgery.
#VisualAbstract: Tislelizumab significantly improves survival outcomes in advanced or metastatic esophageal squamous cell carcinoma
Click to read this study in the Journal of Clinical Oncology.